Verona Pharma Plc ADR (VRNA)

$106.91 +0.12 (0.11%)
Market Cap 8.75B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 872.73
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,871,900
Avg Vol 1,571,794
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 97%
Beta 0.05
Analysts Sell
Price Target $106.00

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
De12
De12 Apr. 2 at 2:05 PM
$ADMA Druckenmiller had Buyouts with $VRNA $CDTX $SWTX next is $ADMA
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 31 at 1:07 PM
$VRNA have a good rest of the week ol friends
0 · Reply
moneybag888
moneybag888 Mar. 27 at 5:00 PM
$DNLI $45 to $65 buyout dejavu $VRNA
0 · Reply
LongLongStock
LongLongStock Mar. 24 at 8:05 AM
$VRNA I miss this stock
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 21 at 3:17 PM
$VRNA Miss you guys
2 · Reply
stjernerogvann
stjernerogvann Mar. 7 at 2:32 PM
$SLS it has been a couple of years since I have seen such a no-brainer investment. The last one was $VRNA which had great COPD data, a unique MOA, easy inhalable delivery, and a huge market. The market beat the share price down after approval and it was a great opportunity. In less than a year Merck bought the company for 8x. $SLS is more compelling: the increase in survival odds from single digits to ~70% will make GPS SOC for AML (and for MM I think) and market capture should be near 100% of applicable patients. And the label will expand. I would be shocked if $SLS is not bought out for at least 15X once results are published.
3 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 5 at 9:38 PM
$IOVA thank you IOVA, $CAPR (jump from December) and $VRNA Crossed $2M today only about 18 months after first crossing a Milli IOVA is on the road to double digits this year, hopefully more
5 · Reply
BioRich
BioRich Mar. 2 at 4:01 PM
$IBRX On my WOW! list. The potential here is insane. Reminds me of $VRNA. We did very well with that. Looks like my late, late selling Friday evening of the trash stock $ALT to buy more $IBRX (even though it was already running) is already paying off. Not, $ALT is a trash stock and only held a position for the potential they pulled off a miracle and fooled someone to give them a deal. That's the ONLY hope for that POS. Follow/Subscribe for more thoughts and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
RunnerSignals
RunnerSignals Feb. 27 at 2:46 PM
volume eruption $JEM $ENSC $ONMD $VEEA $VRNA just printed monster spikes vs avg flow. some +50% to +65%, some 10,000%+ volume jumps
0 · Reply
marked0ne
marked0ne Feb. 24 at 3:08 PM
$CADL i‘ve seen all those reasons before. Over at $VRNA, they prepared for going all the way by themselves. Then got an offer. My buyin was around $13 and i kept all my shares until the BO. If CADL does the same too, i can wait another few years.
5 · Reply
Latest News on VRNA
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Oct 6, 2025, 4:05 PM EDT - 6 months ago

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Sep 24, 2025, 4:05 PM EDT - 7 months ago

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Sep 16, 2025, 6:00 AM EDT - 7 months ago

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Jul 12, 2025, 9:09 PM EDT - 9 months ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

MRK

Major deals involving U.S. drugmakers and biotechs over the past decade

Jul 9, 2025, 1:46 PM EDT - 9 months ago

Major deals involving U.S. drugmakers and biotechs over the past decade

MRK

Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 9 months ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK

Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 9 months ago

Two big reasons why buying Verona was crucial for Merck

Merck has struck a roughly $10 billion deal to buy Verona Pharma

Jul 9, 2025, 10:36 AM EDT - 9 months ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

MRK

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Jul 9, 2025, 8:13 AM EDT - 9 months ago

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Jul 9, 2025, 7:48 AM EDT - 9 months ago

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

MRK

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

Jul 9, 2025, 7:14 AM EDT - 9 months ago

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

MRK

Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 9 months ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK

Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 9 months ago

Merck to acquire Verona Pharma for $10 billion

MRK

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Jul 9, 2025, 6:30 AM EDT - 9 months ago

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

MRK

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Jul 9, 2025, 1:09 AM EDT - 9 months ago

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

MRK

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 11 months ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM LEGN

Verona Pharma Announces June 2025 Investor Conference Participation

May 21, 2025, 6:00 AM EDT - 11 months ago

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

May 6, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Mar 28, 2025, 7:00 AM EDT - 1 year ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 18, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Feb 13, 2025, 6:00 AM EST - 1 year ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Jan 7, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 19, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Announces December 2024 Investor Conference Participation

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 9, 2024, 8:23 AM EST - 1 year ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 2:00 AM EST - 1 year ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 21, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO GRDX

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Sep 5, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Top 3 Health Care Stocks That May Crash In August

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In August

CAH CPRX

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRDN

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 25, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Jun 27, 2024, 9:49 AM EDT - 1 year ago

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024, 9:03 AM EDT - 1 year ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 5:13 PM EDT - 1 year ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 26, 2024, 4:57 PM EDT - 1 year ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR XFOR

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:15 AM EDT - 2 years ago

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

May 9, 2024, 7:00 AM EDT - 2 years ago

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

May 2, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 25, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Andrew Fisher Joins Verona Pharma as General Counsel

Mar 4, 2024, 2:00 AM EST - 2 years ago

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 2:00 AM EST - 2 years ago

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 2:00 AM EST - 2 years ago

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

De12
De12 Apr. 2 at 2:05 PM
$ADMA Druckenmiller had Buyouts with $VRNA $CDTX $SWTX next is $ADMA
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 31 at 1:07 PM
$VRNA have a good rest of the week ol friends
0 · Reply
moneybag888
moneybag888 Mar. 27 at 5:00 PM
$DNLI $45 to $65 buyout dejavu $VRNA
0 · Reply
LongLongStock
LongLongStock Mar. 24 at 8:05 AM
$VRNA I miss this stock
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 21 at 3:17 PM
$VRNA Miss you guys
2 · Reply
stjernerogvann
stjernerogvann Mar. 7 at 2:32 PM
$SLS it has been a couple of years since I have seen such a no-brainer investment. The last one was $VRNA which had great COPD data, a unique MOA, easy inhalable delivery, and a huge market. The market beat the share price down after approval and it was a great opportunity. In less than a year Merck bought the company for 8x. $SLS is more compelling: the increase in survival odds from single digits to ~70% will make GPS SOC for AML (and for MM I think) and market capture should be near 100% of applicable patients. And the label will expand. I would be shocked if $SLS is not bought out for at least 15X once results are published.
3 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 5 at 9:38 PM
$IOVA thank you IOVA, $CAPR (jump from December) and $VRNA Crossed $2M today only about 18 months after first crossing a Milli IOVA is on the road to double digits this year, hopefully more
5 · Reply
BioRich
BioRich Mar. 2 at 4:01 PM
$IBRX On my WOW! list. The potential here is insane. Reminds me of $VRNA. We did very well with that. Looks like my late, late selling Friday evening of the trash stock $ALT to buy more $IBRX (even though it was already running) is already paying off. Not, $ALT is a trash stock and only held a position for the potential they pulled off a miracle and fooled someone to give them a deal. That's the ONLY hope for that POS. Follow/Subscribe for more thoughts and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
RunnerSignals
RunnerSignals Feb. 27 at 2:46 PM
volume eruption $JEM $ENSC $ONMD $VEEA $VRNA just printed monster spikes vs avg flow. some +50% to +65%, some 10,000%+ volume jumps
0 · Reply
marked0ne
marked0ne Feb. 24 at 3:08 PM
$CADL i‘ve seen all those reasons before. Over at $VRNA, they prepared for going all the way by themselves. Then got an offer. My buyin was around $13 and i kept all my shares until the BO. If CADL does the same too, i can wait another few years.
5 · Reply
moneybag888
moneybag888 Jan. 31 at 3:23 AM
$CRSR 🤝 $GME could happen again…deja vu $VRNA 🤝 $MRK
2 · Reply
Ms_P
Ms_P Jan. 21 at 12:43 AM
$GPCR Almost was a year ago Cramer was saying to sell $VRNA 😂 https://finance.yahoo.com/news/jim-cramer-advises-caution-verona-194833698.html https://finance.yahoo.com/news/jim-cramer-structure-therapeutics-don-171325935.html
3 · Reply
JTebow_CWS
JTebow_CWS Jan. 12 at 12:30 PM
$SABS $VRNA $SNY Excellent short explanation. Glad to own shares here. https://youtube.com/shorts/P2cpE8f20HE?si=EC-MPczGItwvTfUP
0 · Reply
Gambaa
Gambaa Jan. 9 at 6:52 PM
$LQDA $INSM $VRNA really gotta wonder… https://x.com/alphahunte79332/status/2009633944535195890?s=46&t=XpQsAPGJtIU5DcxtMNKtOg
0 · Reply
zippewa
zippewa Jan. 9 at 1:56 PM
$VRNA $SABS Come on over to SABS! New Director joins SAB Bio from Verona. Served as CEO until company was bought. Dr. David Zaccardelli is an accomplished biopharmaceutical executive with more than 20 years of experience leading companies through transformational growth, including leading companies from clinical to commercial stage. He most recently served as President and Chief Executive Officer of Verona Pharma until its acquisition by Merck & Co., Inc. Under his leadership, the Company successfully completed two Phase 3 trials, received its first FDA approval, and launched Ohtuvayre ® (ensifentrine). During his tenure, Dr. Zaccardelli was recognized as Executive of the Year at Scrip’s 2023 Awards. P
1 · Reply
Jack_Danielss
Jack_Danielss Jan. 9 at 11:53 AM
$MLTX just love the cash position. $VRNA was the same with bags of cash and a big credit facility
0 · Reply
zippewa
zippewa Jan. 8 at 1:33 PM
$SABS welcome $VRNA crew!
0 · Reply
Rascal7777777
Rascal7777777 Dec. 30 at 4:31 PM
$VRNA I miss this group. We did well. What are we picking next?
3 · Reply
Jack_Danielss
Jack_Danielss Dec. 30 at 1:30 PM
$GLSI give me partnership or acquisition news?! The way this is trending up every day reminds me of $VRNA before its buyout
1 · Reply
bblackm5
bblackm5 Dec. 29 at 7:00 PM
$OMER similar to $VRNA. Awaiting the ascend up and mindful not to sell too early.
0 · Reply
ap20
ap20 Dec. 27 at 12:30 AM
$VRNA Merck at 80 in the fall would have been a pretty good buy. Verona on board now and Cidara on the way. Congrats to those who bought. I didn’t. Might next time I get some $.
0 · Reply
Juststartingout14
Juststartingout14 Dec. 26 at 3:33 PM
$OMER the last biotech I owned that I can compare to this one is $VRNA... It is just a matter of time....
2 · Reply